Press Releases



High Tide acquires top-performing Canna Cabana retail Store

High Tide to Open Canna Cabana in Popular Year-Round Tourist Destination of Banff

CALGARY, AB, Aug. 7, 2020 /CNW/ – High Tide Inc. (“High Tide” or the “Company”) (CSE: HITI) (OTCQB: HITIF) (Frankfurt: 2LY) a retail-focused cannabis corporation enhanced by the manufacturing and distribution of cannabis lifestyle accessories, today announced that the Canna Cabana retail cannabis store located in Unit #L08/09 at 215 Banff Avenue in Banff, Alberta (the “Banff Store”) will be opening on Wednesday, August 12, 2020 after receiving its license from Alberta Gaming Liquor and Cannabis on August 6. The Banff Store marks the Company’s 28(th) location in Alberta and 37(th) retail cannabis store across Canada.


Beleave Update on Stalking Horse Sale Process

TORONTO, Aug. 6, 2020 /CNW/ – Beleave Inc. (CSE:BE) (OTC: BLEVF) (“Beleave” or the “Company”) announced today that the Company, together with its affiliated entities, Beleave Kannabis Corp., Seven Oaks Inc., 9334416 Canada Inc. O/A Medi-Green and My-Grow, Beleave Kannabis Abbotsford Inc. and Beleave Kannabis Chilliwack Inc. (collectively, the “Beleave Group”), and in consultation with Grant Thornton Limited (the “Monitor”), has completed the primary milestone within its Stalking Horse Sale Process.


The Green Organic Dutchman: Q4 and Year End 2019 Financial Results

The Green Organic Dutchman to Release Second Quarter Financial Results

TORONTO, Aug. 6, 2020 /PRNewswire/ – The Green Organic Dutchman Holdings Ltd. (“TGOD” or the “Company”) (TSX: TGOD) (US: TGODF), a leading producer of premium certified organic cannabis, will release its first quarter financial results following the market close on the evening of Wednesday, August 12, 2020. The Company will hold a conference call with analysts on Thursday, August 13, 2020, beginning at 9:00 a.m. (ET). An audiocast of the conference call will be available on a listen-only basis at:



iAnthus Announces Resignation of Elizabeth Stavola as Officer and Director

NEW YORK and TORONTO, Aug. 4, 2020 /PRNewswire/ – iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN) (OTCQX: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, announces the resignation of Elizabeth Stavola, founder of MPX and CBD for Life, as Chief Strategy Officer and as a director of the Company, effective immediately.


GreenAcreage Announces $55 Million Sale-Leaseback Transaction

NEW YORK, Aug. 4, 2020 /PRNewswire/ — GreenAcreage Real Estate Corp. (“GreenAcreage”) announced today that it closed on a sale-leaseback financing transaction in Florida with a leading national cannabis operator (“Tenant”). GreenAcreage acquired the cultivation facility for a total of $55 million. The property will be subject to a long-term, triple-net lease to the Tenant, who will continue to operate the facility.


iAnthus Reports Fiscal 2019 Financial Results and Provides Additional Business Updates

NEW YORK and TORONTO, July 31, 2020 /PRNewswire/ – iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN) (OTCQX: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, reports its financial results for the year ended December 31, 2019. The Company’s Financial Statements for the year ended December 31, 2019 and the related Management’s Discussion & Analysis can be accessed on the Company’s SEDAR profile at www.sedar.com and on the Company’s website.


FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease

SILVER SPRING, Md., July 31, 2020 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). This is the only FDA-approved drug that contains a purified drug substance derived from cannabis. It is also the second FDA approval of a drug for the treatment of seizures associated with TSC.